88238-73-7Relevant academic research and scientific papers
A novel quinoline derivative containing a phenanthroimidazole moiety: Synthesis, physical properties and light-emitting diodes application
Shao, Xiaona,Liu, Wenzhu,Guo, Ruike,Chen, Junfeng,Zhou, Nonglin
, (2021)
The deep-blue emitting material 2-(8-(benzyloxy)quinolin-2-yl)-1-phenyl-1H-phenanthro[9,10-d]imidazole (QL-PPI) which contains 8-(Benzyloxy)quinoline core and phenanthroimidazole moiety, has been designed and synthesized. The non-doped OLED using QL-PPI a
Multifunctional 8-hydroxyquinoline-appended cyclodextrins as new inhibitors of metal-induced protein aggregation
Oliveri, Valentina,Attanasio, Francesco,Puglisi, Antonino,Spencer, John,Sgarlata, Carmelo,Vecchio, Graziella
, p. 8954 - 8964 (2014)
Mounting evidence suggests a pivotal role of metal imbalances in protein misfolding and amyloid diseases. As such, metal ions represent a promising therapeutic target. In this context, the synthesis of chelators that also contain complementary functionali
Development and characterization of BODIPY-derived tracers for fluorescent labeling of the endoplasmic reticulum
Daelemans, Brent,Dehaen, Wim,Manshian, Bella,Pokorny, Jan,Rocha, Susana,Silveira-Dorta, Gaston,Soenen, Stefaan,Startek, Justyna B.,Van der Auweraer, Mark,Vandaele, Johannes,de Jong, Flip
, (2020/01/28)
Visualization of the structure of the Endoplasmic Reticulum (ER) in living cells is important for the understanding of its function. Here we synthesized a library of 8 BODIPY labeledhydroxyquinoline derivatives and evaluated their spectroscopic properties, cytotoxicity, and intracellular localization. The compounds were easily obtained in 34–80% yield. Based on the spectral properties and low cytotoxicity, we selected the quinolin-8-yl pentanoate derivative 17 for in vivo labeling of the ER. Fluorescence staining of the ER was evaluated by comparison with a commercial ER tracker. The molecules here developed are smaller than the alternatives commercially available while still presenting a high specificity towards the ER.
Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease
Hu, Jinhui,Pan, Tingting,An, Baijiao,Li, Zhengcunxiao,Li, Xingshu,Huang, Ling
, p. 512 - 526 (2019/01/03)
Considering the importance of PDE4D inhibition and the modulation of biometals in Alzheimer's disease (AD) therapeutics, we have designed, synthesized and evaluated a series of new clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands fo
2-carboxyl piperazine linked tacrine-8-amino(hydroxyl) quinoline derivative as well as preparation and application
-
Paragraph 0090-0093, (2019/08/06)
The invention relates to the technical field of chemical synthesis, and specifically relates to a 2-carboxyl piperazine linked tacrine-8-amino(hydroxyl) quinoline derivative as well as preparation andapplication. The 2-carboxyl piperazine linked tacrine-8-amino(hydroxyl) quinoline derivative is a chemical compound shown in a formula I (the formula I is shown in the description) or a pharmaceutically acceptable salt thereof, and a solvent chemical compound, an enantiomer, a diastereoisomer, a tautomer or a mixture in any proportion of the chemical compound shown in the formula I or the pharmaceutically acceptable salt thereof, and includes a racemic mixture. Confirmed by a pharmacological test, the kind of chemical compound has an inhibiting effect on the activity of acetylcholinesterase(AChE) and butyrylcholinesterase(BuChE), and belongs to a cholinesterase inhibitor; the chemical compound also has an inhibiting effect on self-aggregation of beta-amyloid protein, and has delayed action on hydrolysis of acetylcholine and self-aggregation of the beta-amyloid protein, thereby improving the effect of the acetylcholine on a synapse, and finally realizing the purpose of effectively treating alzheimer's disease (AD).
Synthesis, characterization and luminescence of gold complexes bearing an NHC ligand based on the imidazo[1,5-a]quinolinol scaffold
Kriechbaum, Margit,Winterleitner, Gerda,Gerisch, Alexander,List, Manuela,Monkowius, Uwe
, p. 5567 - 5575 (2013/11/19)
We report on the synthesis and characterization of an NHC ligand based on the imidazo[1,5-a]quinolinol scaffold. The benzyl-protected NHC precursor was used for the preparation of the corresponding AgI, AuI and AuIII compl
Synthesis and anticonvulsant activity of 1-(8-(benzyloxy)quinolin-2-yl)-6- substituted-4,6-diazaspiro[2,4]heptane-5,7-diones
He, Xianran,Zhong, Min,Zhang, Tao,Yang, Jin,Wu, Zhongyuan,Xiao, Yuling,Guo, Hao,Qiu, Guofu,Hu, Xianming
experimental part, p. 338 - 346 (2012/03/22)
In the present study on the development of new anticonvulsants, 16 new1-(8-(benzyloxy)quinolin-2-yl-6-substituted-4,6-diazaspiro[2,4]heptane-5, 7-diones were synthesized and tested for anticonvulsant activity using the maximal electroshock (MES), subcutan
Synthesis and Anticonvulsant Activity of 1-(2-(8-(benzyloxy)quinolin-2-yl)-1-butyrylcyclopropyl)-3-Substituted Urea Derivatives
He, Xianran,Zhong, Min,Yang, Jin,Wu, Zhongyuan,Xiao, Yuling,Guo, Hao,Hu, Xianming
experimental part, p. 771 - 779 (2012/05/20)
In the present study on the development of new anticonvulsants, 16 new1-(2-(8-(benzyloxy)quinolin-2-yl)-1-butyrylcyclopropyl)-3-substituted urea derivatives were synthesized and tested for anticonvulsant activity using the maximal electroshock seizure, su
A simple chemical tuning of the effective concentration: Selection of single-, double-, and triple-stranded binuclear lanthanide helicates
Terazzi, Emmanuel,Guenee, Laure,Bocquet, Bernard,Lemonnier, Jean-Francois,Favera, Natalia Dalla,Piguet, Claude
experimental part, p. 12719 - 12732 (2010/06/14)
The replacement of terminal 2-benzimidazol-6-carboxypyridine (two internal rotational degrees of freedom) with 2-benzimidazol-8-hydroxyquinoline (one internal rotational degree of freedom) into segmental bis-tridentate ligands in going from L2 and [L32H]2- to [L12D-2H]2- does not significantly affect the structures of the resulting binuclear lanthanide triplestranded helical complexes [Ln2(L2)3]6+, [Ln2(L3-2H)3], and [Ln2(L12b-2H)3] (palindromic helices, intermetallic contact distance 9 A, helical pitch 1.4 nm per turn). However, their thermodynamic assemblies are completely different in solution, as evidenced by the spectacular decrease of the effective concentrations by two orders of magnitude for [L12b-2H] 2-. This key parameter in the [Ln2(L12b-2H)n] (n = 2, 3) complexes is further abruptly modulated along the lanthanide series (Ln = La to Lu), which provides an unprecedented tool for 1) tuning the number of ligand strands in the final helicates, 2) selectively coordinating lanthanides in the various complexes, and 3) controlling the ratio of lanthanide-containing polymers over discrete assemblies.
CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS
-
Page 99, (2010/02/08)
This invention pertains to certain carbamic acid compounds of the following formula, which inhibit HDAC (histone deacetylase) activity wherein: A is independently an unsubstituted or substituted bicyclic C9-10heteroaryl group (e.g., quinolinyl; quinoxalinyl; benzoxazolyl; benzothiazolyl); Q is an acid leader group, and is independently an unsubstituted or substituted, saturated or unsaturated C1 7alkylene group having a backbone length of 4 or less; with the proviso that if A is unsubstituted benzothiazol-2-yl, then Q is an unsaturated group; and with the proviso that if A is unsubstituted quinolin-6-yl, then Q is unsubstituted at the α-position; and with the proviso that A is not benzimidazol-2-yl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both invitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.
